BACKGROUND: Although a majority of patients with amnestic mild cognitive impairment (aMCI) progress to Alzheimer disease, the natural history of nonamnestic MCI (naMCI) is less clear. Noninvasive imaging surrogates for underlying pathological findings in MCI would be clinically useful for identifying patients who may benefit from disease-specific treatments at the prodromal stage of dementia. OBJECTIVE: To determine the characteristic magnetic resonance imaging (MRI) and proton MR spectroscopy (1H MRS) profiles of MCI subtypes. DESIGN: Case-control study. SETTING: Community-based sample at a tertiary referral center. PATIENTS: Ninety-one patients with single-domain aMCI, 32 patients with multiple-domain aMCI, 20 patients with single- or multiple-domain naMCI, and 100 cognitively normal elderly subjects frequency-matched by age and sex. MAIN OUTCOME MEASURES: Posterior cingulate gyrus 1H MRS metabolite ratios, hippocampal volumes, and cerebrovascular disease on MRI. RESULTS: Patients with single-domain aMCI were characterized by small hippocampal volumes and elevated ratios of myo-inositol to creatine levels. Patients with naMCI on average had normal hippocampal volumes and 1H MRS metabolite ratios, but a greater proportion (3 of 20 patients [15%]) had cortical infarctions compared with patients with single-domain aMCI (6 of 91 [7%]). For characterization of MCI subtypes, 1H MRS and structural MRI findings were complementary. CONCLUSIONS: The MRI and 1H MRS findings in single-domain aMCI are consistent with a pattern similar to that of Alzheimer disease. Absence of this pattern on average in patients with naMCI suggests that cerebrovascular disease and other neurodegenerative diseases may be contributing to the cognitive impairment in many individuals with naMCI.
BACKGROUND: Although a majority of patients with amnestic mild cognitive impairment (aMCI) progress to Alzheimer disease, the natural history of nonamnestic MCI (naMCI) is less clear. Noninvasive imaging surrogates for underlying pathological findings in MCI would be clinically useful for identifying patients who may benefit from disease-specific treatments at the prodromal stage of dementia. OBJECTIVE: To determine the characteristic magnetic resonance imaging (MRI) and proton MR spectroscopy (1HMRS) profiles of MCI subtypes. DESIGN: Case-control study. SETTING: Community-based sample at a tertiary referral center. PATIENTS: Ninety-one patients with single-domain aMCI, 32 patients with multiple-domain aMCI, 20 patients with single- or multiple-domain naMCI, and 100 cognitively normal elderly subjects frequency-matched by age and sex. MAIN OUTCOME MEASURES: Posterior cingulate gyrus 1HMRS metabolite ratios, hippocampal volumes, and cerebrovascular disease on MRI. RESULTS:Patients with single-domain aMCI were characterized by small hippocampal volumes and elevated ratios of myo-inositol to creatine levels. Patients with naMCI on average had normal hippocampal volumes and 1HMRS metabolite ratios, but a greater proportion (3 of 20 patients [15%]) had cortical infarctions compared with patients with single-domain aMCI (6 of 91 [7%]). For characterization of MCI subtypes, 1HMRS and structural MRI findings were complementary. CONCLUSIONS: The MRI and 1HMRS findings in single-domain aMCI are consistent with a pattern similar to that of Alzheimer disease. Absence of this pattern on average in patients with naMCI suggests that cerebrovascular disease and other neurodegenerative diseases may be contributing to the cognitive impairment in many individuals with naMCI.
Authors: K Kantarci; C R Jack; Y C Xu; N G Campeau; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; E Kokmen; E G Tangalos; R C Petersen Journal: Neurology Date: 2000-07-25 Impact factor: 9.910
Authors: F Jessen; W Block; F Träber; E Keller; S Flacke; A Papassotiropoulos; R Lamerichs; R Heun; H H Schild Journal: Neurology Date: 2000-09-12 Impact factor: 9.910
Authors: K Kantarci; R C Petersen; B F Boeve; D S Knopman; D F Tang-Wai; P C O'Brien; S D Weigand; S D Edland; G E Smith; R J Ivnik; T J Ferman; E G Tangalos; C R Jack Journal: Neurology Date: 2004-10-26 Impact factor: 9.910
Authors: Kejal Kantarci; M L Senjem; V J Lowe; H J Wiste; S D Weigand; B J Kemp; A R Frank; M M Shiung; B F Boeve; D S Knopman; R C Petersen; C R Jack Journal: AJNR Am J Neuroradiol Date: 2010-03-18 Impact factor: 3.825
Authors: Benoit H Mulsant; Aristotle N Voineskos; Neda Rashidi-Ranjbar; Tarek K Rajji; Sanjeev Kumar; Nathan Herrmann; Linda Mah; Alastair J Flint; Corinne E Fischer; Meryl A Butters; Bruce G Pollock; Erin W Dickie; John A E Anderson Journal: Neuropsychopharmacology Date: 2020-05-18 Impact factor: 7.853
Authors: Angel Piriz; Dolly Reyes; Atul Narkhede; Vanessa A Guzman; Fawad Viqar; Irene B Meier; Mariana Budge; Pedro Mena; Stephen Dashnaw; Joseph Lee; Christiane Reitz; Jose Gutierrez; Luis Campos; Martin Medrano; Rafael Lantigua; Richard Mayeux; Adam M Brickman Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Mekala R Raman; Gregory M Preboske; Scott A Przybelski; Jeffrey L Gunter; Matthew L Senjem; Prashanthi Vemuri; Matthew C Murphy; Melissa E Murray; Bradley F Boeve; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Clifford R Jack; Kejal Kantarci Journal: Neurology Date: 2014-05-02 Impact factor: 9.910